Biotech and Pharmaceuticals
Healthy Returns: How competitive can Roche be in the weight loss drug market?
Headquarters of Roche, multinational pharmaceutical industry on December 27, 2021 in Madrid, Spain. Cristina Arias | Cover | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good afternoon! Roche is one of several drugmakers […]
Read More
Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
Drugmakers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough. Bristol Myers Squibb, AstraZeneca, Eli Lilly and other pharmaceutical companies have spent some $10 billion on deals to acquire or work with radiopharmaceuticals makers. They’ve snapped up smaller upstarts to get their hands on technology that, while in its […]
Read More
Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results
Pfizer‘s experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial, the drugmaker said Saturday. Patients with the condition, called cancer cachexia, who took Pfizer’s treatment saw improvements in body weight, muscle mass, quality of life and physical function, according to […]
Read More
Florida discourages use of mRNA Covid vaccines in older adults
Even as the Covid wave in Florida continues, Gov. Ron DeSantis’ administration is once again advising against the mRNA vaccines: this time in the most vulnerable residents. In updated guidance for health care providers released Thursday, the Florida Health Department and state Surgeon General Joseph Ladapo questioned the safety and effectiveness of the mRNA Covid vaccines from Pfizer […]
Read More
Moderna to cut $1.1 billion in costs and launch 10 new products by 2027 as it charts post-Covid future
Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. Plexi Images | GHI | UCG | Universal Images Group | Getty Images Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid business. […]
Read More
Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer’s drugs
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said it will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer’s drug and highly popular weight loss and diabetes treatments, among other medicines, […]
Read More
Healthy Returns: More than 50 million privately insured adults could be eligible for GLP-1 drugs
Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future […]
Read More
AstraZeneca shares fall 5% on disappointing lung cancer drug trial results
AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results. The Covid-19 vaccine maker was trading at the bottom of the FTSE 100 and dragged the wider healthcare sector lower after data published Monday showed that its experimental […]
Read More
Eli Lilly names insider Lucas Montarce as new finance chief
An Eli Lilly and Company pharmaceutical manufacturing plant is pictured in Branchburg, New Jersey, on March 5, 2021. Mike Segar | Reuters U.S. drugmaker Eli Lilly on Monday said it appointed insider Lucas Montarce as its new chief financial officer, effective immediately. Montarce, who joined Lilly in 2001, has held various finance leadership roles within […]
Read More
Alzheimer’s drug Leqembi promises to give patients more time, but they face a long road to treatment
Hannah Yoon | The Washington Post | Getty Images Leqembi, an Alzheimer’s drug from Biogen and Eisai, isn’t a cure for the mind-damaging disease. But the treatment promises to give patients such as Missie Meeks more time to live their daily lives normally and independently of others. Meeks, an English professor based in Ellisville, Mississippi, […]
Read More